Company Profiles

driven by the PitchBook Platform

Affichem

PRIVATE STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
$3.51M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of therapeutic molecules and theranostic markers. The company eases the treatment of cancer and neurodegenerative diseases through its developed molecules.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
  • 9 rue Saint Joseph
  • 31400 Toulouse
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Affichem’s full profile, request a free trial.

Affichem Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 29-Jun-2012 $3.51M 000.00 Completed Generating Revenue
2. Grant 07-Oct-2011 00.000 000.00 Completed Generating Revenue
1. Accelerator/Incubator 01-Jun-2002 $72.8K $72.8K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Affichem Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
European Commission Government 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Incubateur Midi-Pyrenees Accelerator/Incubator Minority 000 0000 000000 0

Affichem Executive Team (2)

Name Title Board
Seat
Contact
Info
Stéphane Silvente Co-Founder, Chief Executive Officer & Chairman
Marc Poirot Co-Founder, Chief Scientific Officer & Board Member

Affichem Board Members (4)

Name Representing Role Since Contact
Info
Frédéric Thivet Affichem Board Member & Legal Director 000 0000
Marc Poirot Affichem Co-Founder, Chief Scientific Officer & Board Member 000 0000
Michaël Paillasse Ph.D Affichem Board Member & Operating Officer 000 0000
Sandrine Silvente Ph.D Affichem Co-Founder, Co-inventor of Dendrogenins, Board Member and Member of the Scientific Advisory Board 000 0000